Biomarkers for Alzheimer’s Disease: The Road Towards Clinical Implementation

Cerebrospinal fluid (CSF) biomarkers for Alzheimer’s disease (AD) have become the cornerstone of the etiological diagnosis of AD. As such, AD biomarkers are indispensable for selection of the right patient groups in trials targeting AD. Moreover, other CSF biomarkers can provide important information on the effects of treatments on pathology, and for stratification.

For many years, blood analyses for the same AD biomarkers were unattainable, but recent results have shown that they will become a reality. Convincing data generated with new high-sensitivity assays have emerged with a remarkable consistency across different cohorts and independent of the analytical method used. Moreover, other neurodegenerative blood-based biomarkers, such as neurofilament light and more recently glial fibrillary acidic protein, provide information on disease progression and show potential for monitoring treatment effects.

Join this webinar to gain insights into the biomarkers for Alzheimer’s disease and get guidance for clinical implementation.

Speakers

Charlotte Teunissen, Professor in Neurochemistry, Chair of the Neurochemistry Lab, Amsterdam UMC

Charlotte Teunissen (Full Professor in Neurochemistry) aims to improve care of patients with neurological diseases by developing body fluid biomarkers for diagnosis, stratification, prognosis and monitoring treatment responses. Studies of her research group span the entire spectrum of biomarker development, starting with biomarker identification, followed by assay development and validation and extensive clinical validation to ultimately implement novel biomarkers in clinical practice.

Charlotte is responsible for the Alzheimer Center Amsterdam and leads several international biomarker networks, such as the CSF Society and the Alzheimer Association-Global Biomarker Standardization consortium, and the recently founded Coral proteomics consortium. She is the Coordinator of the Marie Curie MIRIADE project, aiming to train 15 novel researchers into accelerated dementia biomarker development.

Message Presenter

Pieter van Bokhoven, Chief Scientific Officer, Head of the Industry Alliance Office of Amsterdam Neuroscience, Amsterdam UMC

Pieter van Bokhoven is the Chief Scientific Officer and Head of the Industry Alliance Office of Amsterdam Neuroscience, Amsterdam UMC. Pieter obtained his PhD in molecular neuroscience in 2011 at the VU University Amsterdam, focusing his research on the molecular underpinning of learning and memory. He published high-impact papers on the topic. He broadened his business experience as an entrepreneur as founding partner of an SME developing applications for pharmaceutical companies.

In his current role Pieter is responsible for initiating research projects for drug development and diagnostics for neurodegeneration. This is always in collaboration with industry partners from biotech and pharma and translational in nature. His focus is on bringing new interventions from the lab to patients at Amsterdam UMC, in early clinical development. Pieter has profound knowledge of molecular targets for drugs for Alzheimer’s disease, novel treatment methods and therapeutic modalities and companion diagnostics.

Message Presenter